Biopharma Briefing: Q1 Trends and Updates
Biopharma saw significant M&A activity in Q1 2025, with 27 transactions totaling $25.2 billion.
Licensing deals reached $56.8 billion, driven by oncology and immunology investments.
Gene therapy and radiopharmaceuticals remained strong areas of focus.
ASCO preview likely to highlight advancements in oncology treatments.
IPO markets were cautious, with four biopharma IPOs raising $770 million.